Condition: Breast Cancer · Adjuvant Therapy · Sponsor: Fujian Medical University Union Hospital
To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast cancer patients with residual tumor (primary breast tumor/axillary lymph nodes) who did not achieve pCR after neoadjuvant therapy
This description comes directly from the study's public registry record.
Chuan Wang · 13515020716 · chuanwang68@qq.com
Silu Wang · 18559171530 · wangsiluaaron@163.com
Always discuss trial participation with your own doctor first.
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05292742